Home·Know Your Companions™·Therapies·TEPMETKO

TEPMETKO (tepotinib)

TherapyMerck KGaA

TEPMETKO (tepotinib) from Merck KGaA is a MET inhibitor used in MET exon 14–altered lung cancer.

Approvals

Indications

Biomarkers

Mapped tests

Where this therapy is approved with a companion diagnostic

Each row represents a defined combination of indication, biomarker criteria, and TEPMETKO. Select a testing pathway to see the eligible companion diagnostic tests.

Indication-specific approvals

Approvals where TEPMETKO is tied to a specific indication and biomarker definition.

Indication	Biomarker criteria	Notes
Non-Small Cell Lung Cancer (NSCLC) Solid Tumor · Lung	MET single nucleotide variants and indels that lead to MET exon 14 skipping		View testing pathway →

Tumor-agnostic approvals

Approvals defined at the solid tumor level where biomarker criteria determine eligibility for TEPMETKO.

No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.

Tests used in these approvals

These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering TEPMETKO for eligible patients.

Test

FoundationOne Liquid CDx

Foundation Medicine, Inc.

Method

NGS

Specimen

Whole blood

1 approvalView test profile →

This view is scoped to TEPMETKO (tepotinib). You can also see how it compares with other therapies and indications on the main Know Your Companions™ map.